Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?".
Croce
Kevin
K
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics / Q000378:metabolism*; D017024:Chemotherapy, Adjuvant; D000077407:Cilostazol; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D000075202:Contraindications; D065731:Cytochrome P-450 CYP2C19; D004347:Drug Interactions; D006801:Humans; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy*; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors; D013777:Tetrazoles / Q000627:therapeutic use*; D013927:Thrombosis / Q000517:prevention & control; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D013777:Tetrazoles; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D000077407:Cilostazol; D013988:Ticlopidine